We report the development of a
lactobionic acid (LA)-modified multifunctional
dendrimer-based carrier system for targeted
therapy of
liver cancer cells overexpressing
asialoglycoprotein receptors. In this study, generation 5 (G5)
poly(amidoamine) (PAMAM)
dendrimers were sequentially modified with
fluorescein isothiocyanate (FI) and LA (or
polyethylene glycol (PEG)-linked LA, PEG-LA), followed by acetylation of the remaining
dendrimer terminal
amines. The synthesized G5.NHAc-FI-LA or G5.NHAc-FI-PEG-LA conjugates (NHAc denotes
acetamide groups) were used to encapsulate a model anticancer
drug doxorubicin (DOX). We show that both conjugates are able to encapsulate approximately 5.0 DOX molecules within each
dendrimer and the formed
dendrimer/DOX complexes are stable under different pH conditions and different aqueous media. The G5.NHAc-FI-PEG-LA conjugate appears to have a better cytocompatibility, enables a slightly faster DOX release rate, and displays better
liver cancer cell targeting ability than the G5.NHAc-FI-LA conjugate without PEG under similar experimental conditions. Importantly, the developed G5.NHAc-FI-PEG-LA/DOX complexes are able to specifically inhibit the growth of the target cells with a better efficiency than the G5.NHAc-FI-LA/DOX complexes at a relatively high DOX concentration. Our results suggest a key role played by the PEG spacer that affords the
dendrimer platform with enhanced targeting and therapeutic efficacy of
cancer cells. The developed LA-modified multifunctional
dendrimer conjugate with a PEG spacer may be used as a delivery system for targeted
liver cancer therapy and offers new opportunities in the design of multifunctional
drug carriers for targeted
cancer therapy applications.